title: Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC).
abstract: BACKGROUND
  Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of cancer-related deaths, worldwide. It is essential to develop an effective prognostic biomarker and determine the mechanisms underlying HCC invasion and metastasis.
  
  
  OBJECTIVE
  This study aimed to investigate the expression of Golgi glycoprotein73 (GP73) and Epithelial-mesenchymal transition (EMT) molecules such as E-cadherin and Vimentin in HCC. We also evaluated the prognostic value of GP73 in HCC.
  
  
  METHODS
  Immunohistochemistry (IHC) was used to determine the expression of GP73 and EMT molecules in 75 HCC specimens and the corresponding paracarcinomatous liver (PCL) tissues. Spearman's correlation test was used to analyze the correlation of GP73 and EMT molecules. Clinicopathological features of the HCC patients were also analyzed. Univariate survival analysis was performed by the Kaplan-Meier method and differences among the groups were analyzed by the Log-rank test.
  
  
  RESULTS
  GP73 expression in HCC was higher compared with PCL tissues (χ2 = 73.60, P < 0.05). EMT molecules were also detected in HCC and PCL tissues. GP73 was negatively correlated with E-cadherin (r = - 0.49, P < 0.05), but positively correlated with Vimentin (r = 0.46, P < 0.05) in HCC. GP73 was correlated with the clinicopathological features including Edmondson grade, vascular invasion and TNM stage (P < 0.05), which was also associated with overall survival (OS) (P < 0.05).
  
  
  CONCLUSIONS
  GP73 was negatively with E-cadherin and positively correlated with Vimentin. It might be associated with aggressive behavior of HCC and had influence on patients' OS. Further research is needed to determine the potential of GP73.
  The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/29 vs/1504046946108618; http://med.motic.com/MoticGallery/Slide?id=3b6a037e-f60e-4c68-9106-41e790de9431&user=2C69F0D6-A478-4A2B-ABF0-BB36763E8025; http://med.motic.com/MoticGallery/Slide?id=a25b5b32-b613-47b0-9f8b-e1e67a95d1bf&user=2C69F0D6-A478-4A2B-ABF0-BB36763E8025.
authors: Yong Xing
authors: YX
authors: Bao
authors: Qian
authors: Q
authors: Cao
authors: Ying
authors: Y
authors: Yang
authors: Rui
authors: R
authors: Mao
authors: Lei
authors: L
authors: Xiao
authors: Hua
authors: H
authors: Zhang
authors: Hua-rong
authors: HR
authors: Zhao
authors: Tumor Department, First Affiliated Hospital of Xinjiang Medical University (XJMU), Urumqi, China. wenhao@126.com.
authors: Hao
authors: H
authors: Wen
mesh_terms: D015703:Antigens, CD; D014408:Biomarkers, Tumor / Q000032:analysis*; D015820:Cadherins / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000737:chemistry* / Q000401:mortality / Q000473:pathology*; D016009:Chi-Square Distribution; D058750:Epithelial-Mesenchymal Transition; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology*; D008565:Membrane Proteins / Q000032:analysis*; D009361:Neoplasm Invasiveness; D011379:Prognosis; D012307:Risk Factors; D015854:Up-Regulation; D014746:Vimentin / Q000032:analysis
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C513384:CDH1 protein, human; D015820:Cadherins; C410824:GOLM1 protein, human; D008565:Membrane Proteins; D014746:Vimentin